Philippe Mathurin
A5101946423- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Alcohol Consumption and Health Effects
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Diet, Metabolism, and Disease
- Organ Transplantation Techniques and Outcomes
- Liver Diseases and Immunity
- Drug-Induced Hepatotoxicity and Protection
- Bariatric Surgery and Outcomes
- Liver physiology and pathology
- Diet and metabolism studies
- Systemic Lupus Erythematosus Research
- Pancreatitis Pathology and Treatment
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Renal Transplantation Outcomes and Treatments
- Eicosanoids and Hypertension Pharmacology
- Meningioma and schwannoma management
- Cannabis and Cannabinoid Research
- Intracranial Aneurysms: Treatment and Complications
- Endoplasmic Reticulum Stress and Disease
- Chronic Lymphocytic Leukemia Research
- Peroxisome Proliferator-Activated Receptors
Hôpital Claude Huriez
2016-2025
Centre Hospitalier Universitaire de Lille
2016-2025
Inserm
2015-2024
Université de Lille
2015-2024
Lille Inflammation Research International Center
2015-2024
Institute for Translational Research in Inflammation
2020-2023
Périnatalité & Risques Toxiques
2023
Université de Picardie Jules Verne
2023
Centre Hospitalier Universitaire Amiens-Picardie
2018-2023
Lille’s Cardiology Hospital
2012-2023
Background & AimsElafibranor is an agonist of the peroxisome proliferator−activated receptor-α and receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, lipid metabolism reduces inflammation. We assessed safety efficacy elafibranor in international, randomized, double-blind placebo-controlled trial patients with nonalcoholic steatohepatitis (NASH).MethodsPatients NASH without cirrhosis were randomly assigned to groups given 80 mg (n = 93), 120 91), or placebo 92) each...
A 6-month abstinence from alcohol is usually required before patients with severe alcoholic hepatitis are considered for liver transplantation. Patients whose not responding to medical therapy have a survival rate of approximately 30%. Since most deaths occur within 2 months, early transplantation attractive but controversial.We selected seven centers The had no prior episodes and scores 0.45 or higher according the Lille model (which calculates ranging 0 1, score ≥ indicating nonresponse an...
Early identification of patients with severe (discriminant function ≥ 32) alcoholic hepatitis (AH) not responding to corticosteroids is crucial. We generated a specific prognostic model (Lille model) identify candidates early on for alternative therapies. Three hundred twenty AH prospectively treated by were included in the development cohort and 118 its validation. Baseline data change bilirubin at day 7 tested. The was logistic regression. combining six reproducible variables (age, renal...
Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast receptors implicated in tumorigenesis angiogenesis hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib had been treated sorafenib.In all, 395 advanced progressed on/after were intolerant randomly assigned (2:1)...
The impact of hepatitis B (HBV) and C (HCV) on patient survival after kidney transplantation is controversial. aims this study were (1) to assess the independent prognostic values HBsAg anti-HCV in a large renal transplant population, (2) compare infected patients with noninfected matched for factors possibly associated graft survival, (3) value biopsy-proven cirrhosis. Eight hundred thirty-four transplanted included: 128 positive (group I), 216 II), 490 without serological markers HBV HCV...
Acute-on-chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin dialysis with the molecular adsorbent recirculating system (MARS) decreases retained substances and improves hemodynamics hepatic encephalopathy (HE). However, its survival impact unknown. In all, 189 patients ACLF were randomized either to MARS (n=95) or standard therapy (SMT) (n=94). Ten (five per group) excluded due protocol violations. addition, 23 (MARS: 19; SMT: 4) from per-protocol (PP) analysis...
Patients with primary biliary cholangitis who have an inadequate response to therapy ursodeoxycholic acid are at high risk for disease progression. Fibrates, which agonists of peroxisome proliferator-activated receptors, in combination acid, shown potential benefit patients this condition.In 24-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 100 had according the Paris 2 criteria receive bezafibrate a daily dose 400 mg (50 patients), or placebo addition continued...
We studied the effects of long-term treatment with interferon on histologic features liver and serum alanine aminotransferase concentrations in patients chronic non-A, non-B hepatitis.
Background/Aims: No study has compared the liver fibrosis progression rates among chronic diseases and risk factors in order to better organize screening strategies.Methods: A total of 4852 patients were retrospectively studied (chronic hepatitis C (HCV) [n=2313], human immunodeficiency virus (HIV)–HCV co-infection (HIV–HCV [n=180]), B (HBV [n=777]), alcoholic disease (ALD [n=701]), primary biliary cirrhosis (PBC [n=406]), genetic hemochromatosis (GH [n=383]) auto-immune (AIH [n=57]) delta...
Tumor necrosis factor-α (TNF-α) may contribute to the progression of acute alcoholic hepatitis (AAH). The aim this study was evaluate efficacy an association infliximab and prednisolone at reducing 2-month mortality rate among patients with severe AAH. Patients AAH (Maddrey score ≥32) were randomly assigned group A receiving intravenous infusions (10 mg/kg) in weeks 0, 2, 4; or B a placebo same times. All received (40 mg/day) for 28 days. Blood neutrophil functional capacities monitored over...